1.23 0.01 (0.82%) | 04-17 16:00 | |||||||||||||
|
|
Short term | ||||
Mid term | ||||
Targets | 6-month : | 1.71 | 1-year : | 1.95 |
Resists | First : | 1.47 | Second : | 1.66 |
Pivot price | 1.32 | |||
Supports | First : | 1.14 | Second : | 0.95 |
MAs | MA(5) : | 1.22 | MA(20) : | 1.37 |
MA(100) : | 1.31 | MA(250) : | 1.74 | |
MACD | MACD : | -0.1 | Signal : | -0.1 |
%K %D | K(14,3) : | 10.4 | D(3) : | 7.2 |
RSI | RSI(14): 42.7 | |||
52-week | High : | 4.3 | Low : | 0.99 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ HOTH ] has closed above bottom band by 24.1%. Bollinger Bands are 25.3% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
If tomorrow: | Open lower | Open higher |
High: | 1.26 - 1.26 | 1.26 - 1.27 |
Low: | 1.15 - 1.15 | 1.15 - 1.16 |
Close: | 1.22 - 1.23 | 1.23 - 1.24 |
Hoth Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It is involved in the development of HT-001, a topical formulation for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; HT-003 to treat inflammatory bowel diseases, as well as acne and psoriasis; HT-004 for treatment of asthma and allergies using inhalational administration; HT-006 to treat lung diseases resulting from bacterial infections; and HT-002, a novel peptide for treating COVID-19. The company is also developing BioLexa Platform, a proprietary, patented, drug compound platform which is in phase I clinical trial for the treatment of eczema; and HT-005 for treating patients with lupus. The company has license agreements with the George Washington University; the University of Maryland; Isoprene Pharmaceuticals, Inc.; the North Carolina State University; Chelexa BioSciences, Inc.; Zylö Therapeutics, Inc., and the University of Cincinnati. It also has a research collaboration agreement with Weill Cornell Medicine to develop HT-003. Hoth Therapeutics, Inc. was incorporated in 2017 and is headquartered in New York, New York.
Mon, 08 Apr 2024
Analysts Offer Predictions for Hoth Therapeutics, Inc.'s Q1 2024 Earnings (NASDAQ:HOTH) - Defense World
Sat, 06 Apr 2024
Hoth Therapeutics' (HOTH) Buy Rating Reiterated at HC Wainwright - Defense World
Thu, 28 Mar 2024
Should You Hold Hoth Therapeutics Inc (HOTH) Stock Thursday Morning? - InvestorsObserver
Wed, 27 Mar 2024
Is Hoth Therapeutics Inc (HOTH) Stock About to Get Hot Wednesday? - InvestorsObserver
Wed, 27 Mar 2024
Hoth Therapeutics' Wholly Owned Subsidiary Merveille.ai, Advances AI-Driven Discovery for Obesity Treatment - PR Newswire
Wed, 27 Mar 2024
Hoth Therapeutics Announces Exercise of Warrants for $4.2 Million Gross Proceeds - PR Newswire
Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
Exchange:
NASDAQ
|
|
Sector:
Healthcare
|
|
Industry:
Biotechnology
|
|
Shares Out | 5 (M) |
Shares Float | 4 (M) |
Held by Insiders | 1.6 (%) |
Held by Institutions | 6.9 (%) |
Shares Short | 218 (K) |
Shares Short P.Month | 76 (K) |
EPS | -2.3 |
EPS Est Next Qtrly | 0 |
EPS Est This Year | 0 |
EPS Est Next Year | 0 |
Book Value (p.s.) | 2.02 |
Profit Margin | 0 % |
Operating Margin | 0 % |
Return on Assets (ttm) | -59.1 % |
Return on Equity (ttm) | -112.6 % |
Qtrly Rev. Growth | 0 % |
Gross Profit (p.s.) | 0 |
Sales Per Share | 0 |
EBITDA (p.s.) | 0 |
Qtrly Earnings Growth | 0 % |
Operating Cash Flow | -8 (M) |
Levered Free Cash Flow | -5 (M) |
PE Ratio | -0.54 |
PEG Ratio | 0 |
Price to Book value | 0.6 |
Price to Sales | 0 |
Price to Cash Flow | -0.72 |
Dividend | 0 |
Forward Dividend | 0 |
Dividend Yield | 0% |
Dividend Pay Date | Invalid DateTime. |
Ex-Dividend Date | Invalid DateTime. |